Vasculitis sistémicas
Publicaciones destacadas
-
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW;(...)Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME .Referencia:Journal Of Allergy And Clinical Immunology 2019.
-
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P;(...)Walsh D; Walters G; Harper L; Jayne D; European Vasculitis Study Group (EUVAS).Referencia:Annals Of The Rheumatic Diseases 2019.
-
Expression and function of IL12/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: Contribution of p40 to Th1-and Th17-mediated inflammatory pathways
Espigol-Frigole, Georgina; Planas-Rigol, Ester; Lozano, Ester; Corbera-Bellalta, Marc; Terrades-Garcia, Nekane;Prieto-Gonzalez, Sergio; Garcia-Martinez, Ana; Hernandez-Rodriguez, Jose; Grau, Josep M; Cid, Maria C.Referencia:Frontiers In Immunology 2018.
-
Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: A mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis
Planas-Rigol, Ester; Terrades-Garcia, Nekane; Corbera-Bellalta, Marc; Lozano, Ester; Alba, Marco A;(...)Prieto-Gonzalez, Sergio; Hernandez-Rodriguez, Jose; Preciado, Sara; Lavilla, Rodolfo; Cid, Maria C.Referencia:Annals Of The Rheumatic Diseases 2017.
-
Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M;(...)Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N .Referencia:New England Journal Of Medicine 2017.
-
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M E; Akuthota, P; Jayne, D; Khoury, P; Klion, A;(...)Philipson, R; Yancey, S W; Steinfeld, J; Weller, P F; Gleich, G J;EGPA Mepolizumab Study Team.Referencia:New England Journal Of Medicine 2017.
-
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
Carmona FD; Vaglio A; Mackie SL; Hernández-Rodríguez J; Monach PA;(...)Morgan AW; González-Gay MA; Martín J Spanish CGA Group; UKGCA Consortium; Vasculitis Clinical Research Consortium.Referencia:American Journal Of Human Genetics 2017.
-
Blocking interferon gamma reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis
Corbera-Bellalta, Marc; Planas-Rigol, Ester; Lozano, Ester; Terrades-Garcia, Nekane; Alba, Marco A;(...)Roux-Lombard, Pascale; Ferlin, Walter G; Dayer, Jean-Michel; Kosco-Vilbois, Marie H; Cid, Maria C.Referencia:Annals Of The Rheumatic Diseases 2016.
-
Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling
Espigol-Frigole, Georgina; Planas-Rigol, Ester; Ohnuki, Hidetaka; Salvucci, Ombretta; Kwak, Hyeongil;Ravichandran, Sarangan; Luke, Brian; Cid, Maria C; Tosato, Giovanna.Referencia:Science Signaling 2016.
-
Changes in biomarkers after therapeutic intervention in temporal arteries cell arteritis
Corbera-Bellalta, Marc; Garcia-Martinez, Ana; Lozano, Ester; Planas-Rigol, Ester; Tavera-Bahillo, Itziar;(...)Fernandez, Pedro L; Roux-Lombard, Pascale; Dayer, Jean-Michel; Rahman, Mahboob U; Cid, Maria C.Referencia:Annals Of The Rheumatic Diseases 2014.